PT2 - Clinical Data and Mode of Action of Myozyme® (alglucosidase alfa)
MYOZYME is indicated for long-term enzyme replacement therapy (ERT) in adults and pediatric patients of all ages with a confirmed diagnosis of Pompe disease (acid α-glucosidase (GAA) deficiency.1 The video presents the pivotal and long-term data of MYOZYME. It also shows the mode of action video of how MYOZYME works on replacing the missing or deficient GAA enzyme in Pompe disease.1
Reference: 1. MYOZYME [summary of product characteristics]. Amsterdam. The Netherlands: Genzyme Europe BV; 2021. View Here
PT3 – Symptomatic Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in Adults
SERB is a European specialty pharmaceutical group focused on prescription medicines which address rare and life-threatening diseases. Following strategic acquisitions and targeted developments, SERB has succeeded in establishing a consistent drugs portfolio focused on niche specialty pharmaceuticals to ensure continuous availability of life-saving medicines and answer unmet medical needs. Our commitment is to continue to offer essential drugs meeting Public Health needs. SERB has extended its Rare Diseases portfolio in both Neurology (with treatments for severe epileptic and neuromuscular conditions) and Metabolic Disorders. This includes Firdapse® for the symptomatic treatment of Lambert Eaton Myasthenic syndrome in adults. Discover more at www.serb.eu. See Firdapse Summary of Product Characteristics on EMA website here.
Please note that this Firdapse® communication concerns European, Middle East and African Health Care Professionals only.